Key Details
Price
$21.20Last Dividend
$0.20Annual Revenue
$15.44 BAnnual EPS
$0.90Annual ROE
10.67%Beta
0.26Events Calendar
Next earnings date:
Feb 07, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Feb 08, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Nov 13, 2024Next split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Despite the recent fluctuations in the market, 2024 has been an excellent year for stocks. The S&P 500 index has provided a total return of about 25% when accounting for dividends throughout this year's trading.
Kenvue's latest earnings report indicates progress, but ongoing challenges, particularly in the Skin, Health, & Beauty sector, imply that significant growth may be difficult in the short term. Although the company is seeing good dividend growth and is reducing costs, rising interest rates and economic issues in China are still affecting its performance. To address these challenges and promote future growth, management is focusing on boosting their online presence and collaborating with influencers.
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) has announced that it will take part in the Morgan Stanley Global Consumer & Retail Conference in New York City. CEO Thibaut Mongon and CFO Paul Ruh will join a fireside chat on Wednesday, December 4, 2024, at 11:45 a.m. Eastern Time. A live stream of the chat can be accessed on investors.kenvue.com, and a recording will be available on the site afterwards.
Kenvue, Inc. (NYSE:KVUE) will hold its Q3 2024 Earnings Conference Call on November 7, 2024, at 8:00 AM ET. The call will feature company representatives including Sofya Tsinis, Thibaut Mongon, and Paul Ruh. Various analysts from major financial institutions will also participate in the discussion.
SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) has released its financial results for the third quarter of the fiscal year, which ended on September 29, 2024.
Kenvue Inc (NYSE:KVUE), known for products like Listerine, Tylenol, Aveeno, and Band-Aid, announced sales that were a bit below expectations, but their earnings exceeded Wall Street's predictions. The company has gained more attention recently due to news that activist investor Starboard Value has invested in it and is considering potential changes.
Can making small changes really improve the appeal of this stock?
Ken Griffin's Citadel has recently acquired 18 million shares of a lesser-known consumer health company.
An activist investor is buying shares in Kenvue.
Starboard Value and Kenvue appear to be on the same page, and the situation could be favorable for creating value.
FAQ
- What is the primary business of Kenvue?
- What is the ticker symbol for Kenvue?
- Does Kenvue pay dividends?
- What sector is Kenvue in?
- What industry is Kenvue in?
- What country is Kenvue based in?
- When did Kenvue go public?
- Is Kenvue in the S&P 500?
- Is Kenvue in the NASDAQ 100?
- Is Kenvue in the Dow Jones?
- When was Kenvue's last earnings report?
- When does Kenvue report earnings?
- Should I buy Kenvue stock now?